Other regions included RIMS2, known to be associated with particularly aggressive breast cancers (Zhang et al., 2021), and APIP, which binds HER3 receptor, leading to the heterodimerisation between HER2 and HER3 and resulting in sustained activation of downstream signalling (Hong et al., 2016). This evidence concerns the gene ERBB3 and breast carcinoma.